Zogenix (ZGNX) Misses Q2 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Zogenix (ZGNX) Misses Q2 EPS by 11c

Zogenix Provides Corporate Update and Reports Second Quarter 2021 Financial Results

August 5, 2021 4:01 PM EDT

Commercial launches of FINTEPLA® in the U.S. and Europe progressing strongly, with total net product sales of $17.5 million and total revenue of $18.8 million in the second quarter, representing quarter-over-quarter increases of 42% and 37%, respectivelyAs of June 30, 2021, over 860 patients have been prescribed FINTEPLA and referred to the REMS program, and there were 290 unique prescribers, an increase of 22% quarter-over-quarter On track to submit supplemental New Drug Application (NDA) seeking to expand FINTEPLAs label for treatment of Lennox-Gastaut syndrome (LGS) in Q3 2021, following positive meeting with U.S. Food and Drug... More